Literature DB >> 17924862

Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.

Andrew J Krentz1, Geraldine Clough, Christopher D Byrne.   

Abstract

Convention partitions the complications of diabetes into two main subtypes. First are the diabetes-specific microvascular complications of retinopathy, nephropathy and neuropathy; second are the atherothrombotic macrovascular complications that account for the majority of premature deaths. Pathological interactions between microvascular and macrovascular complications, for example, nephropathy and macrovascular disease, are common. Similar mechanisms and shared risk factors drive the development and progression of both small and large vessel disease. This concept has therapeutic implications. Mounting evidence points to the need for multifactorial strategies to prevent vascular complications in subjects with diabetes and/or the metabolic syndrome. We advocate a combined therapeutic approach that addresses small and large vessel disease. Preferential use should be made of drug regimens that (i) maximize vascular protection, (ii) reduce the risk of iatrogenic vascular damage and (iii) minimize the increasing problem of polypharmacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17924862     DOI: 10.1111/j.1463-1326.2007.00670.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  47 in total

Review 1.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

2.  High glucose-treated macrophages augment E-selectin expression in endothelial cells.

Authors:  Te-Chuan Chen; Shao-Ju Chien; Hsing-Chun Kuo; Wen-Shih Huang; Jiunn-Ming Sheen; Tseng-Hsi Lin; Chia-Kuang Yen; Mao-Lin Sung; Cheng-Nan Chen
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

3.  Neuroprotective properties of aucubin in diabetic rats and diabetic encephalopathy rats.

Authors:  Hong Yu Xue; Ya Nan Lu; Xue Mei Fang; Yong Ping Xu; Gui Zhen Gao; Li Ji Jin
Journal:  Mol Biol Rep       Date:  2012-07-19       Impact factor: 2.316

4.  Assessment of anti-diabetic activity of peanut shell polyphenol extracts.

Authors:  Xiao-Meng Sun; Hai-Qing Ye; Jing-Bo Liu; Lei Wu; Ding-Bo Lin; Ya-Li Yu; Feng Gao
Journal:  J Zhejiang Univ Sci B       Date:  2018 Oct.       Impact factor: 3.066

Review 5.  Pathogenesis of diabetic cerebral vascular disease complication.

Authors:  Ren-Shi Xu
Journal:  World J Diabetes       Date:  2015-02-15

6.  Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat.

Authors:  Christine Maric-Bilkan; Elizabeth R Flynn; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-26

7.  The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice.

Authors:  Kathryn E Husarek; Paige S Katz; Aaron J Trask; Maarten L Galantowicz; Mary J Cismowski; Pamela A Lucchesi
Journal:  Vascul Pharmacol       Date:  2015-06-30       Impact factor: 5.773

8.  Is diabetic retinopathy related to subclinical cardiovascular disease?

Authors:  Ryo Kawasaki; Ning Cheung; F M Amirul Islam; Ronald Klein; Barbara E K Klein; Mary Frances Cotch; A Richey Sharrett; Daniel O'Leary; Tien Y Wong
Journal:  Ophthalmology       Date:  2010-12-18       Impact factor: 12.079

Review 9.  Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?

Authors:  Alejandro R Chade; Nicholas Stewart
Journal:  J Am Soc Hypertens       Date:  2013-02-19

Review 10.  New drugs for type 2 diabetes mellitus: what is their place in therapy?

Authors:  Andrew J Krentz; Mayank B Patel; Clifford J Bailey
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.